DFX Intelligence

Data Factory

VentureFirminstitutional vcexempt_reporting_adviser

Sanderling Management Company, LLC

Venture Capital

San Mateo, CA

Sanderling has supported over 90 biomedical companies earning consistently high rates of return on its venture investments.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:43c3f8e1-ed39-4852-a16f-5bb66c543dba

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 6:06 AM UTC and rebuilt at most every 15 minutes.

Relationships: 76
Dated events: 40
On other graphs: 0
Observed: Sep 12, 2026 to Sep 17, 2026
57 observations

Across DFX

This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 30
Vintages: 2013 to 2026
Reported GAV: $177Mgross asset value on Form ADV; never dry powder
Funds with fundraising evidence: 3derived
Investments: 37
Portfolio companies: 37
Investments, 12m: 37
Partner-attributed: 0
People: 5
Investment professionals: 5derived
Co-investors: 0derived
LP relationships: 0
Stated sectors: biotech,medtechas stated by the firm
Stated stages: early
Latest Form D: May 7, 2026
Latest ADV filing: Mar 31, 2026
Website: sanderling.com

Funds

Fund	Vintage	Lifecycle	Form D sold	GAV
MHS Capital Partners IN, LLC	2026	Newly closed	$4.0M	n/a
MHS Capital Partners ST, LLC	2026	Newly closed	$8.5M	n/a
MHS Capital Partners CE, LLC	2026	Newly closed	$3.0M	n/a
Neo SPV 4.3, LP	2025	Newly closed	$6.0M	n/a
Neo SPV 4.4, LP	2025	Newly closed	$26.9M	n/a
Sanderling Ventures VII Annex Fund, LP	2017	Harvest	$0	$3.6M
Revelation-Sanderling, LLC	2016	Wound down	n/a	$0
Sanderling Ventures VII (canada), L.P.	2014	Harvest	n/a	$20.1M
Sanderling Ventures VII, L.P.	2013	Harvest	n/a	$81.1M
Sanderling Venture Partners VI, L.P.	n/a	Unknown	n/a	$13.3M
Sanderling Venture Partners V Co-Investment Fund, L.P.	n/a	Unknown	n/a	$5.8M
Sanderling V Beteiligungs Gmbh & Co. Kg	n/a	Unknown	n/a	$383,804
Sanderling Venture Partners II, L.P.	n/a	Wound down	n/a	$641,403
Sanderling IV Limited Partnership	n/a	Unknown	n/a	$42,001
Sanderling Venture Partners IV, L.P.	n/a	Wound down	n/a	$0
Sanderling IV Biomedical Co-Investment Fund, L.P.	n/a	Wound down	n/a	$207,505
Sanderling Venture Partners IV Co-Investment Fund, L.P.	n/a	Wound down	n/a	$0
Health Velocity Capital III Executive Network Fund, L.P.	n/a	Fundraising	$0	n/a
Health Velocity Capital III, L.P.	n/a	Fundraising	$0	n/a
Wavepeak Ventures Fund I, LP	n/a	Fundraising	$0	n/a
Sanderling Ventures Partners VI Co-Investment Fund, L.P.	n/a	Unknown	n/a	$27.9M
Sanderling IV [feri Trust] Venture Partners	n/a	Wound down	n/a	$46,793
Sanderling IV Biomedical, L.P.	n/a	Wound down	n/a	$17,621
Sanderling VI Beteiligungs Gmbh & Co. Kg	n/a	Unknown	n/a	$152,274
Sanderling V Strategic Exit Fund, L.P.	n/a	Unknown	n/a	$10.6M

Investments

round size is never this investor's check

Company	State	Stage	Round size	Partner	Attribution	Observed
Actimis	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Aderis	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Artielle	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Asteres	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cylene	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
DalCor	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
DepoTech	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Glycomine	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Liphorus	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Naviscan	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Sotera	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
TheraVida	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
UltraBridge UltraBridge, Inc.	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
info@sanderling.com	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Therillia	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Altor BioScience	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
CalciMedica	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
CardioNet	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
Dendreon	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
Digirad	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
Endocyte	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
GeminX	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
Intermune	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
Ista	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026
LineaGen	n/a	n/a	n/a	n/a	Unknown	Sep 13, 2026

Co-investors

pairs come only from shared rounds and listings

Investor	Co-investor	Shared deals	Shared companies	Last observed	Strength
Sofinnova Investments, Inc.	Sanderling Management Company, LLC	1	1	Sep 13, 2026	One time
Sanderling Management Company, LLC	Artis Ventures Management, L.P.	1	1	Sep 16, 2026	One time
Sanderling Management Company, LLC	Mission Biocapital	1	1	Sep 16, 2026	One time
Sanderling Management Company, LLC	Revival Healthcare Capital LLC	1	1	Sep 16, 2026	One time
Sanderling Management Company, LLC	Artis Capital Management, L.P.	1	1	Sep 16, 2026	One time
Sanderling Management Company, LLC	Advent Life Sciences LLP	1	1	Sep 16, 2026	One time
Sanderling Management Company, LLC	RHO Capital Partners	1	1	Sep 16, 2026	One time

Relationships

Invested in (37)

→ TherilliaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ ArtielleCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ ActimisCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ AderisCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ AsteresCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ CyleneCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ DalCorCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ DepoTechCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ GlycomineCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ LiphorusCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ NaviscanCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ SoteraCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ TheraVidaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ UltraBridge UltraBridge, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ info@sanderling.comCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ TheregenCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ Altor BioScienceCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ CalciMedicaCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ CardioNetCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ DendreonCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ DigiradCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ EndocyteCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ GeminXCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ IntermuneCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ ISTACompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ LineaGenCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ MetaventionCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ NeoMendCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ PaciraCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
→ RegeneronCompanyPortfolio listing
Sep 13, 2026 to presentfactThe subject's own site
and 7 more

Employs (9)

→ Timothy MillsPersonManaging Director
factThe subject's own site
→ Robert G. McneilPersonFounding Partner (September 4, 1943 – July 23, 2021)
factThe subject's own site
→ Pierre BeauparlantPersonVenture Partner
factThe subject's own site
→ Timothy MillsPersonManaging Director
factThe subject's own site
→ Robert G. McNeilPersonFounding Partner (September 4, 1943 – July 23, 2021)
factThe subject's own site
→ Timothy Curtis MillsPersonManaging Director
Jan 1, 2000 to presentfactForm ADV
→ Frederick Alexander MiddletonPersonManaging Director
Dec 1, 1987 to presentfactForm ADV
→ Peter C. M. MacwilliamsPersonManaging Director
Dec 1, 2017 to Apr 29, 2020inferenceForm ADV
→ Robert Gordon McneilPersonManaging Director
Dec 1, 1987 to Apr 4, 2022inferenceForm ADV

Manages (30)

→ Sanderling Ventures VII, L.P.FundVenture Capital Fund
Mar 27, 2013 to presentfactForm ADV
→ Sanderling Ventures VII (canada), L.P.FundVenture Capital Fund
Mar 28, 2014 to presentfactForm ADV
→ Sanderling Ventures VII Annex Fund, LPFundVenture Capital Fund
Mar 21, 2017 to presentfactForm ADV
→ Sanderling Venture Partners IV, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling VI Limited PartnershipFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling V Strategic Exit Fund, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling IV Limited PartnershipFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling Venture Partners II, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling VI Beteiligungs Gmbh & Co. KgFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling IV [feri Trust] Venture PartnersFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling V Limited PartnershipFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling Venture Partners IV Co-Investment Fund, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ MHS Capital Partners IN, LLCFundInferred from address
inferenceForm D
→ Neo SPV 4.3, LPFundInferred from address
inferenceForm D
→ MHS Capital Partners ST, LLCFundInferred from address
inferenceForm D
→ Health Velocity Capital III Executive Network Fund, L.P.FundInferred from address
inferenceForm D
→ Wavepeak Ventures Fund I, LPFundInferred from address
inferenceForm D
→ Neo SPV 4.4, LPFundInferred from address
inferenceForm D
→ Health Velocity Capital III, L.P.FundInferred from address
inferenceForm D
→ MHS Capital Partners CE, LLCFundInferred from address
inferenceForm D
→ Sanderling V Beteiligungs Gmbh & Co. KgFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling Venture Partners VI, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling Ventures Partners VI Co-Investment Fund, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Revelation-Sanderling, LLCFundVenture Capital Fund
Mar 21, 2016 to presentfactForm ADV
→ Sanderling V Biomedical Co-Investment Fund, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling Venture Partners V, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling V Biomedical, LPFundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling IV Biomedical Co-Investment Fund, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling IV Biomedical, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV
→ Sanderling Venture Partners V Co-Investment Fund, L.P.FundVenture Capital Fund
Mar 30, 2012 to presentfactForm ADV

Dated events

38 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Sep 16, 2026
Person left
Timothy Mills (Managing Director) no longer on the team page of Sanderling Management Company, LLC
The subject's own siteobserved 2 days ago
Occurred
Sep 16, 2026
Person left
Robert G. McNeil (Founding Partner (September 4, 1943 – July 23, 2021)) no longer on the team page of Sanderling Management Company, LLC
The subject's own siteobserved 2 days ago

Show 38 bookkeeping events

First seen by DFX
Sep 17, 2026
date not stated
Dendreon no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Metavention no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Intermune no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Ventritex no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Altor BioScience no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Regeneron no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Endocyte no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
LineaGen no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Vical no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Pacira no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
NeoMend no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
CardioNet no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Stereotaxis no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
ISTA no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Xoma no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Digirad no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Stentor no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Theregen no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
CalciMedica no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
GeminX no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
Taligen no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 17, 2026
date not stated
ViaCyte no longer listed on Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Altor BioScience: acquired by ImmunityBio on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
LineaGen: acquired by Bionano Genomics on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
NeoMend: acquired by C.R. Bard on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Intermune: listed (NASDAQ: ITMN) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Endocyte: listed (NASDAQ: ECYT) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Vical: listed (NASDAQ: VICL) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Digirad: listed (NASDAQ: DRAD) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Regeneron: listed (NASDAQ: REGN) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
DepoTech: acquired by SkyePharma on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Xoma: listed (NASDAQ: XOMA) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
CalciMedica: listed (NASDAQ: CALC) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
ISTA: listed (NASDAQ: ISTA) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Dendreon: listed (NASDAQ: DNDN) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
CardioNet: listed (NASDAQ: BEAT) on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
Naviscan: acquired by CMR Naviscan on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page
First seen by DFX
Sep 14, 2026
date not stated
GeminX: acquired by Cephalon on or before 2026-09-13 (no date published), per Sanderling Management Company, LLC's portfolio page

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 website (Form ADV), 1 work email (firm website) · as of 2026-09-17

Also named here, with no published line of their own (reach them through the firm): Timothy Mills (Managing Director), Robert G. Mcneil (Founding Partner (September 4, 1943 – July 23, 2021)), Pierre Beauparlant (Venture Partner), Timothy Mills (Managing Director), Robert G. McNeil (Founding Partner (September 4, 1943 – July 23, 2021)), Timothy Curtis Mills (Managing Director), Frederick Alexander Middleton (Managing Director).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance